NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet 390, 2627–2642 (2017).
Kovesdy, C. P. Epidemiology of chronic kidney disease: an update 2022. Kidney Int. Suppl. 12, 7–11 (2022).
Eckel, R. H. & Cornier, M. A. Update on the NCEP ATP-III emerging cardiometabolic risk factors. BMC Med. 12, 115 (2014).
Ndumele, C. E. et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation 148, 1606–1635 (2023).
Tchernof, A. & Després, J. P. Pathophysiology of human visceral obesity: an update. Physiol. Rev. 93, 359–404 (2013).
Article CAS PubMed Google Scholar
Ye, C. et al. Causal associations of obesity with chronic kidney disease and arterial stiffness: a mendelian randomization study. J. Clin. Endocrinol. Metab. 107, e825–e835 (2022).
Chang, A. R. et al. Adiposity and risk of decline in glomerular filtration rate: meta-analysis of individual participant data in a global consortium. BMJ 364, k5301 (2019). This meta-analysis demonstrates that increased BMI is an independent risk factor for GFR decline and death in the general population and those with CKD.
Hsu, C. Y., McCulloch, C. E., Iribarren, C., Darbinian, J. & Go, A. S. Body mass index and risk for end-stage renal disease. Ann. Intern. Med. 144, 21–28 (2006).
Zhang, S. Y. et al. Metformin triggers a kidney GDF15-dependent area postrema axis to regulate food intake and body weight. Cell Metab. 35, 875–886.e5 (2023). This study demonstrates that metformin mediates weight loss through a kidney GDF15-dependent area postrema axis.
Article CAS PubMed Google Scholar
Weisinger, J. R., Kempson, R. L., Eldridge, F. L. & Swenson, R. S. The nephrotic syndrome: a complication of massive obesity. Ann. Intern. Med. 81, 440–447 (1974).
Article CAS PubMed Google Scholar
D’Agati, V. D., Fogo, A. B., Bruijn, J. A. & Jennette, J. C. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am. J. Kidney Dis. 43, 368–382 (2004).
Kambham, N., Markowitz, G. S., Valeri, A. M., Lin, J. & D’Agati, V. D. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. 59, 1498–1509 (2001).
Article CAS PubMed Google Scholar
Chen, H. M. et al. Podocyte lesions in patients with obesity-related glomerulopathy. Am. J. Kidney Dis. 48, 772–779 (2006).
Chen, H. M. et al. Obesity-related glomerulopathy in China: a case series of 90 patients. Am. J. Kidney Dis. 52, 58–65 (2008).
D’Agati, V. D. et al. Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis. Nat. Rev. Nephrol. 12, 453–471 (2016).
Praga, M. et al. Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis. Nephrol. Dial. Transpl. 16, 1790–1798 (2001).
Serra, A. et al. Renal injury in the extremely obese patients with normal renal function. Kidney Int. 73, 947–955 (2008).
Article CAS PubMed Google Scholar
Griffin, K. A., Kramer, H. & Bidani, A. K. Adverse renal consequences of obesity. Am. J. Physiol. Ren. Physiol. 294, F685–F696 (2008).
Hall, J. E., do Carmo, J. M., da Silva, A. A., Wang, Z. & Hall, M. E. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ. Res. 116, 991–1006 (2015).
Article CAS PubMed Google Scholar
Schorr, U., Blaschke, K., Turan, S., Distler, A. & Sharma, A. M. Relationship between angiotensinogen, leptin and blood pressure levels in young normotensive men. J. Hypertens. 16, 1475–1480 (1998).
Article CAS PubMed Google Scholar
Hall, J. E., do Carmo, J. M., da Silva, A. A., Wang, Z. & Hall, M. E. Obesity, kidney dysfunction and hypertension: mechanistic links. Nat. Rev. Nephrol. 15, 367–385 (2019).
Goodfriend, T. L., Ball, D. L., Egan, B. M., Campbell, W. B. & Nithipatikom, K. Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension 43, 358–363 (2004).
Article CAS PubMed Google Scholar
Jeon, J. H. et al. A novel adipokine CTRP1 stimulates aldosterone production. FASEB J. 22, 1502–1511 (2008).
Article CAS PubMed Google Scholar
Mallamaci, F. et al. ACE inhibition is renoprotective among obese patients with proteinuria. J. Am. Soc. Nephrol. 22, 1122–1128 (2011).
Article CAS PubMed Google Scholar
Kim, S. et al. The adipose renin-angiotensin system modulates systemic markers of insulin sensitivity and activates the intrarenal renin-angiotensin system. J. Biomed. Biotechnol. 2006, 27012 (2006).
Henegar, J. R. et al. Catheter-based radiorefrequency renal denervation lowers blood pressure in obese hypertensive dogs. Am. J. Hypertens. 27, 1285–1292 (2014).
Article CAS PubMed Google Scholar
Xu, X., Huang, X., Zhang, L., Qin, Z. & Hua, F. Adiponectin protects obesity-related glomerulopathy by inhibiting ROS/NF-κB/NLRP3 inflammation pathway. BMC Nephrol. 22, 218 (2021).
Article CAS PubMed Google Scholar
Hall, J. E. et al. Obesity-induced hypertension: role of sympathetic nervous system, leptin, and melanocortins. J. Biol. Chem. 285, 17271–17276 (2010).
Article CAS PubMed Google Scholar
Mansukhani, M. P., Wang, S. & Somers, V. K. Chemoreflex physiology and implications for sleep apnoea: insights from studies in humans. Exp. Physiol. 100, 130–135 (2015).
Hall, M. E. et al. Obesity, hypertension, and chronic kidney disease. Int. J. Nephrol. Renovasc Dis. 7, 75–88 (2014).
Eddy, A. A. & Fogo, A. B. Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J. Am. Soc. Nephrol. 17, 2999–3012 (2006).
Article CAS PubMed Google Scholar
Benomar, Y. et al. Central resistin overexposure induces insulin resistance through Toll-like receptor 4. Diabetes 62, 102–114 (2013).
Article CAS PubMed Google Scholar
Yano, Y. et al. Differential impacts of adiponectin on low-grade albuminuria between obese and nonobese persons without diabetes. J. Clin. Hypertens. 9, 775–782 (2007).
Sharma, K. et al. Adiponectin regulates albuminuria and podocyte function in mice. J. Clin. Invest. 118, 1645–1656 (2008).
Fang, F. et al. Deletion of the gene for adiponectin accelerates diabetic nephropathy in the Ins2+/C96Y mouse. Diabetologia 58, 1668–1678 (2015).
Article CAS PubMed Google Scholar
Ohashi, K. et al. Exacerbation of albuminuria and renal fibrosis in subtotal renal ablation model of adiponectin-knockout mice. Arterioscler. Thromb. Vasc. Biol. 27, 1910–1917 (2007).
Article CAS PubMed Google Scholar
Briffa, J. F., McAinch, A. J., Poronnik, P. & Hryciw, D. H. Adipokines as a link between obesity and chronic kidney disease. Am. J. Physiol. Ren. Physiol. 305, F1629–F1636 (2013).
Aizawa-Abe, M. et al. Pathophysiological role of leptin in obesity-related hypertension. J. Clin. Invest. 105, 1243–1252 (2000).
Article CAS PubMed Google Scholar
Huby, A. C. et al. Adipocyte-derived hormone leptin is a direct regulator of aldosterone secretion, which promotes endothelial dysfunction and cardiac fibrosis. Circulation 132, 2134–2145 (2015).
Article CAS PubMed Google Scholar
Belin de Chantemèle, E. J., Mintz, J. D., Rainey, W. E. & Stepp, D. W. Impact of leptin-mediated sympatho-activation on cardiovascular function in obese mice. Hypertension 58, 271–279 (2011).
de Vries, A. P. et al. Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease. Lancet Diabetes Endocrinol. 2, 417–426 (2014).
留言 (0)